CV Therapeutics Announces Exercise of Over-Allotment Option of 1,350,000 Shares of Common Stock
August 18 2006 - 8:00AM
PR Newswire (US)
PALO ALTO, Calif., Aug. 18 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) announced today that the
underwriters of CV Therapeutics' public offering of 9,000,000
shares of its common stock have exercised their option to purchase
an additional 1,350,000 shares of common stock at the purchase
price of $9.50 per share to cover over-allotments. The closing of
this additional purchase option will increase the aggregate number
of shares sold in this offering to 10,350,000. A registration
statement relating to these securities has been filed with and
declared effective by the Securities and Exchange Commission. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state. About CV Therapeutics CV
Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology
to the discovery, development and commercialization of novel, small
molecule drugs for the treatment of cardiovascular diseases. CV
Therapeutics' approved products include Ranexa(R) (ranolazine
extended- release tablets) and ACEON(R) (perindopril erbumine)
Tablets. Ranexa is indicated for the treatment of chronic angina in
patients who have not achieved an adequate response with other
antianginal drugs, and should be used in combination with
amlodipine, beta-blockers or nitrates. In addition, CV Therapeutics
co-promotes ACEON(R), an ACE inhibitor, for reduction of the risk
of cardiovascular mortality or nonfatal myocardial infarction in
patients with stable coronary artery disease and treatment of
essential hypertension. CV Therapeutics also has other clinical and
preclinical drug development candidates and programs, including
regadenoson, which is being developed for potential use as a
pharmacologic stress agent in myocardial perfusion imaging studies.
Regadenoson has not been approved for marketing by any regulatory
authorities. Except for the historical information contained
herein, the matters set forth in this press release are
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially,
including additional need for capital; regulatory review and
approval of our products; special protocol assessment agreement;
the conduct and timing of clinical trials; commercialization of
products; market acceptance of products; product labeling;
concentrated customer base; and other risks detailed from time to
time in CV Therapeutics' SEC reports, including its Quarterly
Report on Form 10-Q for the quarter ended June 30, 2006. CV
Therapeutics disclaims any intent or obligation to update these
forward-looking statements. DATASOURCE: CV Therapeutics, Inc.
CONTACT: Investors, Dan Spiegelman, SVP & Chief Financial
Officer, +1-650-384-8509, or Christopher Chai, Vice President,
Treasury and Investor Relations, +1-650-384-8560, or Media, John
Bluth, Senior Director, Corporate Communications, +1-650-384-8850,
all of CV Therapeutics, Inc. Web site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Aug 2023 to Aug 2024